JP4907833B2 - 透明水性麻酔剤組成物 - Google Patents

透明水性麻酔剤組成物 Download PDF

Info

Publication number
JP4907833B2
JP4907833B2 JP2002503273A JP2002503273A JP4907833B2 JP 4907833 B2 JP4907833 B2 JP 4907833B2 JP 2002503273 A JP2002503273 A JP 2002503273A JP 2002503273 A JP2002503273 A JP 2002503273A JP 4907833 B2 JP4907833 B2 JP 4907833B2
Authority
JP
Japan
Prior art keywords
propofol
pharmaceutical composition
parenteral administration
aqueous pharmaceutical
administration according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002503273A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003535893A5 (enExample
JP2003535893A (ja
Inventor
スリカンス パイ
サンギータ リヴァンカー
シルパ コチャレカー
Original Assignee
ブハラット セルムズ アンド ヴァクシンズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブハラット セルムズ アンド ヴァクシンズ リミテッド filed Critical ブハラット セルムズ アンド ヴァクシンズ リミテッド
Publication of JP2003535893A publication Critical patent/JP2003535893A/ja
Publication of JP2003535893A5 publication Critical patent/JP2003535893A5/ja
Application granted granted Critical
Publication of JP4907833B2 publication Critical patent/JP4907833B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2002503273A 2000-06-21 2000-12-14 透明水性麻酔剤組成物 Expired - Fee Related JP4907833B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN573/MUM/2000 2000-06-21
IN573MU2000 IN187686B (enExample) 2000-06-21 2000-06-21
PCT/IN2000/000124 WO2001097796A1 (en) 2000-06-21 2000-12-14 Clear aqueous anaesthetic composition

Publications (3)

Publication Number Publication Date
JP2003535893A JP2003535893A (ja) 2003-12-02
JP2003535893A5 JP2003535893A5 (enExample) 2008-02-07
JP4907833B2 true JP4907833B2 (ja) 2012-04-04

Family

ID=11097257

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002503273A Expired - Fee Related JP4907833B2 (ja) 2000-06-21 2000-12-14 透明水性麻酔剤組成物

Country Status (26)

Country Link
US (1) US7138387B2 (enExample)
EP (1) EP1299095B1 (enExample)
JP (1) JP4907833B2 (enExample)
KR (1) KR100810066B1 (enExample)
CN (1) CN1254237C (enExample)
AP (1) AP2002002674A0 (enExample)
AT (1) ATE267592T1 (enExample)
AU (2) AU2001235972B2 (enExample)
BG (1) BG107463A (enExample)
BR (1) BR0017268A (enExample)
CA (1) CA2414064C (enExample)
DE (1) DE60011149T2 (enExample)
DK (1) DK1299095T3 (enExample)
EA (1) EA005589B1 (enExample)
ES (1) ES2222271T3 (enExample)
HU (1) HUP0301646A3 (enExample)
IL (1) IL153387A0 (enExample)
IN (1) IN187686B (enExample)
MX (1) MXPA02012611A (enExample)
NO (1) NO20025999D0 (enExample)
NZ (1) NZ523643A (enExample)
PL (1) PL359624A1 (enExample)
PT (1) PT1299095E (enExample)
WO (1) WO2001097796A1 (enExample)
YU (1) YU2703A (enExample)
ZA (1) ZA200300336B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN188917B (enExample) * 2000-12-07 2002-11-23 Bharat Surums & Vaccines Ltd
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
CA2470500C (en) * 2001-12-28 2012-05-15 Guilford Pharmaceuticals, Inc. Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol
BR0307518A (pt) * 2002-02-01 2004-12-28 Shimoda Biotech Pty Ltd Composição farmacêutica
CN100438861C (zh) 2002-07-29 2008-12-03 变换药品公司 含水2,6-二异丙基苯酚药物组合物
US7550155B2 (en) 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
SI1585548T1 (sl) * 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
US20090192230A1 (en) * 2004-01-14 2009-07-30 Koichi Takeda Propofol-containing fat emulsion preparation
WO2006030450A2 (en) * 2004-09-13 2006-03-23 Bharat Serums & Vaccines Ltd. Stable emulsion compositions for intravenous administration having antimicrobial preservative efficacy
EP1928412B1 (en) * 2005-08-12 2015-09-16 Bharat Serums & Vaccines Ltd. Aqueous anaesthetic compositions comprising propofol
WO2007128866A2 (en) * 2006-05-09 2007-11-15 Novobion Oy Novel chemical compositions
US8563221B2 (en) * 2008-03-11 2013-10-22 3M Innovative Properties Company Phototools having a protective layer
WO2010148288A2 (en) * 2009-06-19 2010-12-23 Lyotropic Therapeutics, Inc. Pharmaceutical formulations with low aqueous levels of free unbound drug
US9096712B2 (en) 2009-07-21 2015-08-04 3M Innovative Properties Company Curable compositions, method of coating a phototool, and coated phototool
WO2011034845A1 (en) 2009-09-16 2011-03-24 3M Innovative Properties Company Fluorinated coating and phototools made therewith
KR101781659B1 (ko) 2009-09-16 2017-09-25 쓰리엠 이노베이티브 프로퍼티즈 컴파니 플루오르화된 코팅 및 그로 제조된 포토툴
US8268067B2 (en) * 2009-10-06 2012-09-18 3M Innovative Properties Company Perfluoropolyether coating composition for hard surfaces
EP2345427A1 (de) * 2010-01-14 2011-07-20 SapioTec GmbH Flurankomplex
EP2484350B1 (de) * 2011-02-04 2016-04-20 Roewer, Norbert, Univ.-Prof. Dr. med. Pharmazeutische Zubereitung, enthaltend einen Komplex eines Propofolsalzes mit einem Cyclodextrin
AU2013273764B2 (en) * 2011-11-29 2016-05-05 Zoetis Services Llc Pharmaceutical compositions
EP2785352B1 (en) * 2011-11-29 2020-03-11 Jurox Pty Ltd Stable injectable pharmaceutical compositions comprising 2-hydroxypropyl-beta-cyclodextrin and alfaxalone
CN103263404B (zh) * 2012-04-28 2017-12-01 中国人民解放军军事医学科学院放射与辐射医学研究所 一种复合麻醉药物
IL275725B (en) 2012-08-21 2022-08-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
EP3407875A4 (en) * 2016-01-29 2019-09-04 Cuda Anesthetics, LLC AQUEOUS PHARMACEUTICAL FORMULATION WITH PROPOFOL
FR3117337B1 (fr) 2020-12-10 2023-04-28 Centre Hospitalier Univ De Lille Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA962214B (en) * 1995-04-10 1996-10-07 Farmarc Nederland Bv Pharmaceutical composition

Also Published As

Publication number Publication date
YU2703A (sh) 2006-03-03
WO2001097796A1 (en) 2001-12-27
EA200300047A1 (ru) 2003-06-26
PL359624A1 (en) 2004-08-23
MXPA02012611A (es) 2004-07-30
DE60011149D1 (de) 2004-07-01
EP1299095A1 (en) 2003-04-09
US20040014718A1 (en) 2004-01-22
NO20025999L (no) 2002-12-13
DE60011149T2 (de) 2005-07-07
BG107463A (en) 2003-11-28
NZ523643A (en) 2004-05-28
EP1299095B1 (en) 2004-05-26
AU3597201A (en) 2002-01-02
DK1299095T3 (da) 2004-10-11
CN1254237C (zh) 2006-05-03
HUP0301646A2 (hu) 2003-09-29
US7138387B2 (en) 2006-11-21
CN1454085A (zh) 2003-11-05
EA005589B1 (ru) 2005-04-28
ATE267592T1 (de) 2004-06-15
HUP0301646A3 (en) 2005-06-28
PT1299095E (pt) 2004-10-29
IN187686B (enExample) 2002-06-08
AP2002002674A0 (en) 2002-12-31
ES2222271T3 (es) 2005-02-01
ZA200300336B (en) 2004-04-08
IL153387A0 (en) 2003-07-06
JP2003535893A (ja) 2003-12-02
CA2414064A1 (en) 2001-12-27
NO20025999D0 (no) 2002-12-13
KR100810066B1 (ko) 2008-03-05
AU2001235972B2 (en) 2005-07-21
KR20030023875A (ko) 2003-03-20
CA2414064C (en) 2013-01-08
BR0017268A (pt) 2003-05-27

Similar Documents

Publication Publication Date Title
JP4907833B2 (ja) 透明水性麻酔剤組成物
AU2001235972A1 (en) Clear aqueous anaesthetic composition
US7678776B2 (en) Inclusion complexes of butylphthalide with cyclodextrin or its derivatives, a process for their preparation and the use thereof
AU1253899A (en) Pharmaceutical compositions containing cyclodextrins and taxoids
JP2003535893A5 (enExample)
KR102843054B1 (ko) 멜록시캄 조성물, 제제 및 이의 제조 방법 및 응용
EA034565B1 (ru) Композиции левосимендана для внутривенного введения в виде инфузии или инъекции и концентрата для инфузии
AU2011264919A1 (en) Formulations including amiodarone and salts thereof and methods of their manufacture and use
KR20080042155A (ko) 가용화제로서의 산을 포함하는 아가트로반 제제
BR112013005763B1 (pt) Injeção de 5a-androstano-3ss, 5, 6ss-triol e método para prrparação da injeção
EA008776B1 (ru) Жидкая стабильная композиция оксазафосфорина с месной
JP2009504634A (ja) プロポフォールを含む水性麻酔剤組成物
WO2021090183A1 (en) Liquid melphalan composition
JP3917820B2 (ja) オザグレルナトリウム含有注射液およびその安定化方法
JP7767153B2 (ja) ポリエーテル系化合物の使用
JP4475405B2 (ja) 医薬組成物
UA75620C2 (en) Stable pharmaceutical form of paclitaxel and method for the preparation thereof
WO2019094819A2 (en) Intravenous delivery systems for chemotherapy drugs
CN108653204B (zh) 一种多烯磷脂酰胆碱注射液药物组合物及其制备方法
CZ20024044A3 (cs) Čirá, vodná kompozice obsahující anestetikum
DE112023000659T5 (de) Neue Naproxen-Natrium-Präparate zur parenteralen Verabreichung
JP2025537030A (ja) 高濃度のオピランセリンを含む医薬組成物
WO2018038687A1 (en) Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex
EA023081B1 (ru) Инъекционная лекарственная форма флупиртина

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110310

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110603

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110804

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111104

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111130

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111221

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120112

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150120

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees